A library of resources to help you understand how to effectively manage GLP-1 in Pharmacy Benefits
Webinars I Whitepaper I Fact Sheet I Blog
GLP‑1 medications have moved far beyond diabetes management—reshaping obesity care, pharmacy practice, and the broader healthcare marketplace. But with rapid innovation comes increasing complexity, regulatory scrutiny, and clinical risk.
In this pharmacist‑led webinar, InnovativeRx Strategies pulls back the curtain on GLP‑1s 2.0, exploring what’s changed, what’s coming next, and what decision‑makers must understand now. From emerging next‑generation agents and expanded indications to evolving formulary strategies, utilization management, and safety considerations, this session delivers a clear, evidence‑based look at the new GLP‑1 landscape.
How should organizations manage GLP-1s on the pharmacy benefit in 2025? This drug category continues to be a hot topic as innovation. Watch this webinar for an exploration of the data, the latest innovations in the space and our strategic recommendations for approaching this drug category in the future. Walk away with practical talking points for your leadership team to address inevitable questions from your plan members.
Led by Innovative’s in-house pharmacists and pharmaceutical experts, this session is one you won’t want to bypass.
This whitepaper from Innovative Rx Strategies examines the growing impact of GLP-1 medications—originally developed for diabetes but now widely used for obesity and other conditions—on US pharmacy benefit plans. It details the rapid expansion and projected market growth of GLP-1s, the significant clinical benefits and side effects, and the financial challenges posed by high drug costs and increasing demand. The report reviews new and pending FDA indications, emerging delivery forms, and strategies for managing the financial implications for health plan sponsors, such as restrictive coverage, utilization management, and alternative payment models. It also highlights the limited near-term relief from generics and the evolving landscape of direct-to-consumer cash programs. A central focus is on balancing access, cost, and long-term sustainability for employer health plans in the face of surging interest in GLP-1 therapies
This fact sheet provides a comprehensive overview of GLP-1 medications for diabetes and obesity, intended to inform plan sponsors and employers about current market trends, clinical benefits, risks, financial impacts, coverage issues, and strategic considerations.
Health care costs are expected to rise by 8% in 2025, with experts pointing to GLP-1 medications as drivers of this trend. GLP-1s are the injectable agents—Glucagon-like peptide-1 (GLP-1) agonists and the combination agents, Glucagon-like peptide-1 agonists with glucose-dependent insulinotropic polypeptides (GLP-1/GIP). First discovered for the treatment of diabetes, these medications were found to have multiple impacts on the body that led to weight loss.
